CMS Influence Over Rx Industry Could Change Culture At FDA – Millennium
The increasing influence of the Centers for Medicare & Medicaid Services within the prescription drug industry could create opportunities for a "cultural shift" at FDA, Millennium Senior VP-R&D Strategy and Operations Abie Celniker said
You may also be interested in...
FDA has revised its timeline for the "Critical Path" drug development initiative to reflect more pressing matters, including drug safety issues, Acting Deputy Commissioner for Operations Janet Woodcock said
An FDA working group will be formed by year-end to consider the development of a guidance on biomarkers
The Medicare drug benefit will make the Centers for Medicare & Medicaid Services at least as important to the pharmaceutical market as FDA, former CMS Administrator Tom Scully predicts